Related Experiment Video
Updated: Aug 9, 2025
Isolation of Human Endometrial Stromal Cells for In Vitro Decidualization
Published on: September 1, 2018
tRF-20-S998LO9D inhibits endometrial carcinoma by upregulating SESN2
Tianye Qian1, Xinnian Yu2, Andi Xu3
1Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, 210009, China.
Abstract:
Aim: To explore the roles of transfer RNA-derived small RNAs (tsRNAs) in endometrial carcinoma (EC). Materials & methods: tsRNA profiles for EC from TCGA were analyzed. The functions and mechanisms of tsRNA were explored using in vitro experiments. Results: 173 dysregulated tsRNAs were identified. After validating in EC tissues and serumal exosome samples from EC patients, a downregulated tsRNA in both EC tissues and serumal exosomes (i.e., tRF-20-S998LO9D) was observed. Exosomal tRF-20-S998LO9D had an area under the curve of 0.768. tRF-20-S998LO9D overexpression inhibited proliferation, migration and invasion and promoted apoptosis of EC cells and tRF-20-S998LO9D knockdown further confirmed its effects. Further analyses showed that tRF-20-S998LO9D upregulated SESN2 in protein levels. Conclusion: tRF-20-S998LO9D inhibits EC cells by upregulating SESN2.
Insights
Transfer RNA-derived small RNAs (tsRNAs) play a role in endometrial carcinoma (EC). A specific tsRNA, tRF-20-S998LO9D, inhibits EC cell growth by increasing SESN2 levels.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Endometrial carcinoma (EC) is a common gynecological malignancy.
- Transfer RNA-derived small RNAs (tsRNAs) are emerging as critical regulators in various cancers.
- The specific roles of tsRNAs in EC pathogenesis remain largely unexplored.
Purpose of the Study:
- To investigate the involvement of tsRNAs in endometrial carcinoma.
- To identify specific tsRNAs that could serve as diagnostic biomarkers or therapeutic targets for EC.
Main Methods:
- Analysis of tsRNA expression profiles in EC patient data (TCGA).
- In vitro experiments to elucidate the functional mechanisms of identified tsRNAs.
- Validation of tsRNA expression in EC tissues and serum exosomes.
Main Results:
- 173 dysregulated tsRNAs were identified in EC.
- A specific tsRNA, tRF-20-S998LO9D, was found downregulated in EC tissues and serum exosomes.
- Overexpression of tRF-20-S998LO9D inhibited EC cell proliferation, migration, and invasion, while promoting apoptosis.
- tRF-20-S998LO9D was shown to upregulate SESN2 protein levels.
Conclusions:
- tRF-20-S998LO9D functions as a tumor suppressor in endometrial carcinoma.
- The mechanism involves the upregulation of SESN2, leading to inhibition of EC cell progression.
- tRF-20-S998LO9D holds potential as a biomarker and therapeutic agent for EC.
